Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00152893
Status:
COMPLETED
Last Update Posted:
2013-07-19
First Post:
2005-09-08
Brief Title:
To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities
Sponsor:
Johane Allard
Organization:
University Health Network Toronto
Study Overview
Official Title:
The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In HIV patients fasting insulin levels decrease with chromium supplementation This study is to determine if chromium nicotinate supplementation at 400ugday for 16 weeks will improve insulin resistance in HIV patients with metabolic abnormalities
Detailed Description:
This study is a randomized double-blind placebo-controlled crossover study where patients will be supplemented for 16 weeks with either chromium nicotinate 400 ugday or placebo and then crossover to the opposite treatment for another 16 weeks Each soft gel capsule of chromium contains 200ug of chromium and patients will take 1 capsule twice a day or its placebo Placebo contains di-calcium phosphate in a soft gel capsule and its appearance is similar to the chromium capsules
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 015 027 | None | None | None |